Spanish media coverage this month points to a broad shift in how Alzheimer's disease is being approached, moving from symptom-based diagnosis toward precision medicine. Revista Pharma Market reported
According to Diario de Sevilla, Hospital San Agustín has introduced a pioneering test that detects Alzheimer's through a blood analysis. Diario Córdoba reported that neurologist Eduardo Agüera, based
PR Noticias framed the wider change as a move from diagnosis by symptoms to precision medicine. Infosalus reported that SEMNIM, Spain's nuclear medicine society, stressed that nuclear medicine plays a
Taken together, the reports describe two connected developments: simpler tools for finding the disease earlier, and a growing need to identify the right patients before treatment begins. The blood tes
The material does not include figures on accuracy, cost or availability for the blood test, nor details on which drugs SEMNIM was referring to, so those points remain open.
What to watch next: whether blood-based biomarkers spread to more Spanish hospitals and how patient selection for the new Alzheimer's drugs develops in practice.
Spanish outlets report a move away from symptom-based Alzheimer's diagnosis toward blood biomarkers and targeted drugs.